Please login to the form below

Not currently logged in
Email:
Password:

CTI

This page shows the latest CTI news and features for those working in and with pharma, biotech and healthcare.

Vernalis accepts £33m takeover offer from Ligand Pharma

Vernalis accepts £33m takeover offer from Ligand Pharma

and aminopeptidase inhibitor tosedostat for leukaemia, which is partnered with CTI Biopharma.

Latest news

  • CTI slumps as Servier-partnered lymphoma drug fails CTI slumps as Servier-partnered lymphoma drug fails

    CTI slumps as Servier-partnered lymphoma drug fails. After major setback CTI, has promising myelofibrosis candidate to fall back on. ... gemcitabine in aggressive B-cell NHL, but found that CTI’s drug was unable to improve progression-free survival (PFS

  • Baxalta and CTI complete filing for Jakafi rival in US Baxalta and CTI complete filing for Jakafi rival in US

    Baxalta and CTI complete filing for Jakafi rival in US. Myelofibrosis candidate pacritinib aiming for accelerated approval. ... dose of Novartis/Incyte's drug, which according to CTI accounts for the bulk of patients taking Jakafi in the US.

  • Baxter and CTI's Jakafi rival clears phase III trial Baxter and CTI's Jakafi rival clears phase III trial

    Baxter and CTI's Jakafi rival clears phase III trial. Myelofibrosis candidate pacritinib moves closer to market. ... Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m deal.

  • CTI launches cancer drug Pixuvri in UK CTI launches cancer drug Pixuvri in UK

    Cell Therapeutics Inc (CTI) has launched its cancer treatment Pixuvri in the UK. ... it any, effective treatment options,' said CTI's president and CEO Dr James Bianco.

  • Baxter licenses cancer drug from CTI in $172m deal Baxter licenses cancer drug from CTI in $172m deal

    Baxter licenses cancer drug from CTI in $172m deal. Pacritinib is being investigated to treat blood disorder myelofibrosis. ... CTI is on track to initiate a second phase III trial of pacritinib before year-end and expects to complete patient enrolment

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics